69 MARTINDALE CENTER FOR THE STUDY OF PRIVATE ENTERPRISE HALMED. (2026a). Distribution, manufacturing and inspection: International cooperation. HALMED. (2026b). Medicinal products: Procedure for granting marketing authorisation | instructions for applicants. Hiller, J. S., & Dresga, S.P. (1996). Progress and challenges of privatization: The Croatian experience. Journal of International Law, 17, 393–413. Hina. (2014). Croatia’s HALMED regulator among best European medicine agencies. Hornstein Tomić, C., & Taylor, K. (2018). Youth unemployment, the brain drain and education policy in Croatia: A call for joining forces and for new visions. Policy Futures in Education, 16, 501–514. doi: 10.1177/1478210317751267 HZZO raising supplementary health insurance price from February 2026. (2025, December 30). Croatia Week. IDA Ireland. (2026). Key players in Ireland’s pharmaceutical manufacturing space. Inić, S., & Flegar, V. (2021). Adolf Thierry and the first pharmaceutical factory in Southeast Europe. Pharmazie, 76, 119–125. doi: 10.1691/ph.2021.0140 INNOTAX. (2026). R&D tax incentives in Croatia. International Monetary Fund. (2025). IMF executive board concludes 2025 Article IV consultation with Republic of Croatia. International Trade Administration. (n.d.). Healthcare technologies resource guide: Croatia. U.S. Department of Commerce. Jakovljevic, M., Lazarevic, M., Milovanovic, O., & Kanjevac, T. (2016). The new and old Europe: East-west split in pharmaceutical spending. Frontiers in Pharmacology, 7. doi: 10.3389/fphar.2016.00018 JGL. (2011). Presentation of the new JGL corporate identity. JGL. (2026). We are discovering new paths and making progress for the future. Kanavos, P., Fontrier, A.-M., Gill, J., & Efthymiadou, O. (2020). Does external reference pricing deliver what it promises? Evidence on its impact at national level. European Journal of Health Economics, 21, 129–151. doi: 10.1007/s10198-019-01116-4 Krka. (2015). Krka opens a new plant for the production of active pharmaceutical ingredients in Krško. Krka. (2024). Annual report 2024. Krka. (2025). Development strategy. Liebman, H. M. (1986). Comments on the effects of workers’ selfmanagement on Yugoslav Joint Ventures. Maryland Journal of International Law, 10. Manufacturing Chemist. (2013). Pliva opens new US$100m oral solid forms facility in Zagreb. Maybury, J. (2015). Pharmaceutical pricing in Croatia: A comparison of ordinances in 2013 versus 2009 and their potential savings to provide future guidance. Generics and Biosimilars Initiative Journal, 4, 79–89. Ministry of Economy, Republic of Croatia. (n.d.-a). HAMAG-BICRO. Ministry of Economy, Republic of Croatia. (n.d.-b). Measures to promote research and development. Ministry of Economy, Republic of Croatia. (n.d.-c). Recovery and Resilience Plan. Ministry of Foreign Affairs in Denmark. (2024). Healthcare and pharmaceuticals. Ministry of Science and Education. (2023). Research infrastructure development roadmap of the Republic of Croatia 2023 –2027. Meulenbelt, M., Sommer, J., Robert, A., Boyle, C., & Vermulst, A. (2025.) EU pharma package: Sharp new tools with limited protections. Sidley. Mordor Intelligence (2026). Croatia pharmaceutical market size & share analysis - growth trends and forecast (2026 – 2031). N1. (2022) Bio-pharma companies Pfizer, Sobi invest €100m in new plant near Zagreb. Nolen, N., & Balling, S. (2021). Parallel trade of pharmaceuticals and its problems in the EU. Centre for European Policy Network. Observatory of Economic Complexity. (n.d.). Pharmaceutical products in Croatia trade. OECD, European Observatory on Health Systems and Policies. (2025). State of health in the EU: Croatia country health profile 2025. Ornaghi, C. (2009). Mergers and innovation in big pharma. International Journal of Industrial Organization, 27, 70–79. doi: 10.1016/j.ijindorg.2008.04.003 PETOŠEVIĆ. (2013). Is Croatia ready? Pezer, S., (2021, February 5). Parliament adopts National Development Strategy until 2030. Hina. PLIVA d.d. (n.d.). Encyclopedia.com. Polpharma Group (n.d.). About Polpharma Group. PwC. (2024). Economic footprint of the pharmaceutical industry in Europe. Rudge, D. (2026, February 5). Krka doubles down on vertical integration with €140m investment push. Generics Bulletin. Samsung Biologics. (2026). Milestones. Third-largest generic drug firm born as Barr finalises acquisition of Pliva. (2006, October 25). Reuters. Toshev, A., Mihaylova, A. A., Madzharov, V., Petkova-Gueorguieva, E., Kirilov, B., Mirchev, D., & Gueorguiev, S. (2025). The European Union’s dependence on imports of active pharmaceutical ingredients from third countries – challenges and EU initiatives. Pharmacia, 72, 1–6. doi: 10.3897/pharmacia.72.e172383 Watt, A. (2025, June 9). The European market access lag: 2021–2024. Pharmaceutical Technology. World Bank. (2020, May). Croatia: Value for money in spending on pharmaceuticals.
RkJQdWJsaXNoZXIy MTA0OTQ5OA==